Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men

Blood Coagulation and Fibrinolysis

Volumn 14, Issue 7, 2003, Pages 677-684

  Johansson, Susanne ^a   Wåhlander, Karin ^a,b   Larson, Göran ^b   Ohlsson, Lis ^a   Larsson, Marita ^a   Eriksson, Ulf G ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anticoagulant; Direct thrombin inhibitor; Melagatran; Pharmacodynamics; Pharmacokinetics

Indexed keywords

MELAGATRAN; PROTHROMBIN COMPLEX; THROMBIN INHIBITOR;

ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING TIME; BLOOD CLOTTING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; MALE; NORMAL HUMAN; PAIN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY;

ADULT; ANTICOAGULANTS; AREA UNDER CURVE; AZETIDINES; BENZYLAMINES; BIOLOGICAL AVAILABILITY; BLOOD COAGULATION; BLOOD COAGULATION TESTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCINE; HALF-LIFE; HEMORRHAGE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PHARMACOKINETICS; THROMBIN;

EID: 0142218380     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200310000-00010     Document Type: Article

References (32)

1. Claeson G. Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system. Blood Coagul Fibrinolysis 1994; 5:411-436.
2. Hauptmann J, Stürzebecher J. Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 1999; 93:203-241.
3. Weitz JI, Hirsch J. New anticoagulant drugs. Chest 2001; 119 (1 suppl):95S-107S.
4. Tapson VF, Hull RD. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin. Clin Chest Med 1995; 16:281-294.
5. Gustafsson D, Nyström J-E, Carlsson S, Bredberg U, Eriksson U, Gyzander E, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101:171-181.
6. Eriksson UG, Bredberg U, Hoffmann K-J, Thuresson A, Gabrielsson M, Ericsson H, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003; 31:294-305.
7. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79:110-118.
8. Boström SL, Hansson GFH, Kjaer M, Sarich TC. Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin, on the endogenous thrombin potential in venous blood from healthy male subjects. Blood Coagul Fibrinolysis 2003; 14:457-462.
9. Sarich TC, Eriksson UG, Mattsson C, Woltz M, Frison L, Fager G, et al. Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects. Thromb Haemost 2002; 87:300-305.
10. Eriksson BI, Carlsson S, Halvarsson M, Risberg B, Mattsson C. Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat. Thromb Haemost 1997; 78:1404-1407.
11. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding time of thrombin inhibitors and warfarin in the rat. Thromb Res 1999; 94:187-197.
12. Mikulski A, Elg M, Gustafsson D. The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. Thromb Res 2001; 101:477-482.
13. Mehta JL, Chen L, Nichols WW, Mattsson C, Gustafsson D, Saldeen TG. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery. J Cardiovasc Pharmacol 1998; 31:345-351.
14. Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, et al. Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis. J Thromb Haemost 2003; 1:999-1004.
15. Eriksson M, Larsson A, Saldeen T, Mattsson C. Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig. Thromb Haemost 1998; 80:1022-1026.
16. Eriksson H, Eriksson UG, Frison L, Hansson PO, Held P, Holmström M, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999; 81:358-363.
17. Wåhlander K, Lapidus L, Olsson C-G, Thuresson A, Eriksson UG, Larsson G, et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thromb Res 2002; 107:93-99.
18. Eriksson H, Wåhlander K, Gustafsson D, Welin LT, Frison L, Schulman S, for the THRIVE Investigators. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1:41-47.
19. Eriksson BI, Ögren M, Eriksson UG, Kälebo P, Ahnfelt L, Björkström S, et al. Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies. Thromb Res 2002; 105:371-378.
20. Eriksson BI, Arfwidsson A-C, Frison L, Eriksson UG, Bylock A, Kälebo P, et al. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery. Thromb Haemost 2002; 87:231-237.
21. Heit JA, Colwell CW, Francis CW, Ginsberg JS, Berkowitz SD, Whipple J, Peters G. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161:2215-2221.
22. Petersen P, Grind M, Adler J, for the SPORTIF II Investigators. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003; 41:1445-1451.
23. Eriksson BI, Bergqvist D, Kälebo P, Dahl OE, Lindbratt S, Bylock A, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360:1441-1447.
24. Francis CW, Davidson BL, Berkowitz SD, Lotke PA, Lieberman JR, Webster, AK, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann Intern Med 2002; 137:648-655.
25. Owren PA, Aas K. The control of dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Lab Invest 1951; 3:201-208.
26. Elg M, Gustafsson D, Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thromb Haemost 1997; 78:1286-1292.
27. Larsson M, Logren U, Ahnoff M, Lindmark B, Abrahamsson P, Svennberg H, Persson B-A. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766:47-45.
28. Mattsson C, Menschiek-Lundin A, Wåhlander K, Lindahl TL. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thromb Haemost 2001; 86:611-615.
29. Andersson L-O, Barrowcliffe TW, Holmer E, Johnson EA, Sims GEC. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res 1976; 9:575-583.
30. Fenyvesi T, Jörg I, Harenberg J. Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation. Clin Chem 2002; 48:1791-1794.
31. Fenyvesi T, Jörg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002; 28:361-368.
32. Nylander S, Mattsson C. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coagul Fibrinolysis 2003; 14:159-167.